Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study

Anti-PLA2R antibody levels at baseline and 6 months serve as robust predictors of treatment response in PMN and outperform proteinuria in early remission assessment. These findings support the integration of anti-PLA2R monitoring into standard clinical practice for personalized management and therapy adjustment in PMN.